Free
Meeting Abstracts  |   October 2001
Activation of μ-Opioid Receptor Induces Expression of c-fos  and junB  via  Mitogen-activated Protein Kinase Cascade
Author Affiliations & Notes
  • Takehiro Shoda, M.D.
    *
  • Kazuhiko Fukuda, M.D., Ph.D.
  • Hisatoshi Uga, M.D.
  • Hiroyuki Mima, M.D.
  • Hitoshi Morikawa, M.D., Ph.D.
    *
  • *Instructor, †Professor and Chair, Department of Anesthesia, Kyoto University Hospital. ‡Graduate Student, Department of Anesthesia, Kyoto University Graduate School of Medicine.
  • Received from the Department of Anesthesia, Kyoto University Hospital, Kyoto, Japan.
Article Information
Meeting Abstracts   |   October 2001
Activation of μ-Opioid Receptor Induces Expression of c-fos  and junB  via  Mitogen-activated Protein Kinase Cascade
Anesthesiology 10 2001, Vol.95, 983-989. doi:
Anesthesiology 10 2001, Vol.95, 983-989. doi:
THE opioid receptors, classified into μ, δ, and κ types on the basis of the differences in binding affinities for ligands, mediate a variety of biologic effects of opioids. 1 In particular, recent studies using knock-out mice show that the μ-opioid receptor (MOR) plays a major role in the pharmacologic effects of morphine, the most popular opioid analgesic, such as analgesia, respiratory depression, addiction, physical dependence, and neuroendocrine effects. 2,3 At the cellular level, pharmacologic, physiologic, and biochemical studies showed that activation of the opioid receptors induces inhibition of adenylate cyclase, inhibition of voltage-dependent Ca2+channels, and activation of inward rectifier K+channels. 4 These cellular responses are inhibited by pretreatment with pertussis toxin (PTX), indicating that the opioid receptors are coupled with the PTX-sensitive G-protein (Gior Goor both).
Molecular biologic techniques, including cloning of the complementary DNAs (cDNAs) and expression of the cloned cDNAs in cultured cells, have enabled us to further examine the intracellular signal-transduction mechanisms activated by the opioid receptors. 5 We and other groups have previously demonstrated that extracellular signal–regulated kinase (ERK), a class of the mitogen-activated protein kinases, is activated by the opioid receptors expressed from cloned cDNAs in cultured cells. 6–8 Mitogen-activated protein kinases transmit various stimuli from the cell surface to the cytoplasm and nucleus and are known to be involved in cell proliferation, differentiation, and long-term potentiation in neurons. 9,10 ERK is a serine/threonine kinase that has been shown to affect many aspects of cellular functions by phosphorylating a number of intracellular proteins, including transcription factors, protein kinases, and cytosolic phospholipase A2. 11 Previously, we reported that opioid receptor activation in the presence of A23187, a calcium ionophore, resulted in an increase in arachidonate release, suggesting that cPLA2is activated by the opioid receptors, possibly through phosphorylation by ERK. 6 However, the other opioid-activated cellular responses mediated by mitogen-activated protein kinases have not been thoroughly analyzed.
In the current study we examined opioid-induced immediate early gene expression in cultured cells stably transfected with the cloned MOR cDNA. Our data demonstrate that MOR activation induces expression of the immediate early genes c-fos  and junB  , via  the PTX-sensitive G-protein and ERK cascade.
Materials and Methods
Materials
The CHO cell line stably expressing the cloned rat MOR (CROR-B22 cells) was described previously. 12 The following materials were purchased:[D-Ala2, N  -Me-Phe4,Gly-ol5]enkephalin (DAMGO; Peninsula Laboratories, Belmont, CA); morphine hydrochloride (Takeda, Osaka, Japan); culture medium and TRIzol reagent (GIBCO, Grand Island, NY); bovine calf serum (HyClone, Logan, UT); PTX (Funakoshi, Tokyo, Japan); PD98059 (Calbiochem, La Jolla, CA); [α-32P]dCTP and [γ-32P]ATP (Amersham-Pharmacia, Uppsala, Sweden); PathDetect Trans- and Cis-Reporting system plasmids (Stratagene, La Jolla, CA); Luciferase Assay System (Promega, Pittsburgh, PA); FuGene 6 Transfection Reagent and β-galactosidase reporter assay system (Roche, Indianapolis, IN); and other reagents (Wako, Osaka, Japan; Nacalai Tesque, Kyoto, Japan; and Sigma, St. Louis, MO).
Cell Culture
CROR-B22 cells were maintained in minimum essential medium α containing deoxyribonucleosides and ribonucleosides supplemented with 6% bovine calf serum, penicillin G (50 units/ml), streptomycin sulfate (50 μg/ml) and G418 (300 μg/ml) in the humidified atmosphere of 95% air and 5% CO2at 37°C.
RNA Blot Hybridization Analysis
CROR-B22 cells were grown to confluence in 60-mm culture dishes, deprived of serum for 24 h, and then stimulated with agonists for the indicated times. After stimulation, total RNA was extracted with use of TRIzol reagent according to the manufacturer’s instruction. Total RNAs were analyzed essentially as described previously. 13 The RNAs were electrophoresed in 1% agarose gel and transferred to a nylon membrane (Pall). The hybridization probes for c-fos  and junB  were the 0.5-kb-pair Acc  I/ Ava  I fragment in the fourth exon of the human c-fos  genome 14 (TaKaRa, Kyoto, Japan) and 1.5-kb-pair Eco  RI fragment in the mouse junB  cDNA (kindly provided by Daniel Nathans, M.D., Johns Hopkins University School of Medicine, Baltimore, MD), 15 respectively. The hybridization probe for β-actin was the 0.4-kb-pair Hin  fI fragment of the human β-actin gene 16 (Wako, Osaka, Japan). The probes were labeled with [α-32P]dCTP by the random primer method. 17 Autoradiography was performed at −80°C with an intensifying screen for 2 days.
Elk-1– and AP-1–mediated Transcriptional Reporter Assay
CROR-B22 cells were plated at 2 or 3 × 106cells per well in 6-well-plates and incubated for about 24 h before transfection. Transfection was performed with use of the FuGene 6 transfection reagent according to the manufacturer’s instruction.
For the Elk-1-mediated transcriptional reporter assay, 18 CROR-B22 cells were transfected with the three expression plasmids of the PathDetect Trans-Reporting system (Stratagene), pFA2-Elk1 (encoding a fusion protein of Gal4 DNA binding domain and Elk-1 transactivation domain), pFR-Luc (constructed by cloning the entire coding sequence of the firefly luciferase downstream of a basic promoter element, TATA box, and joined to five tandem repeats of the 17-bp Gal4 binding element), and pSVβgal (encoding the Escherichia coli  β-galactosidase). To perform the AP-1–mediated transcriptional reporter assay, 19 cells were transfected with the two expression plasmids of the PathDetect Cis-Reporting system, pAP1-Luc (constructed by cloning the entire coding sequence of the firefly luciferase downstream of a TATA box and joined to seven tandem repeats of the 7-bp AP-1 binding element) and pSVβgal.
At 24 h after transfection, incubation medium was replaced with serum-free minimum essential medium α, and the cells were incubated for a further 24 h. After serum starvation, cells were stimulated with 1 μm MOR agonists for 5 h at 37°C and washed twice with phosphate-buffered saline. The luciferase and β-galactosidase activity in the cell lysate was measured by the Luciferase Assay System and β-galactosidase reporter assay system, respectively. The luciferase activity reflects Elk-1- or AP-1–mediated transcriptional activity. The β-galactosidase activity is measured to compare the transfection efficiency between experiments. The luciferase activity was normalized to each β-galactosidase activity.
Electrophoretic Mobility Shift Assay
CROR-B22 cells were grown to confluence in 100-mm dishes, serum-starved for 24 h, and stimulated by 1 μm agonists for 60 min at 37°C. Then cells were washed twice with phosphate-buffered saline, suspended in hypotonic buffer A [10 mm HEPES (pH, 7.6), 15 mm KCl, 2 mm MgCl2, 0.1 mm EDTA, 1 mm dithiothreiol (DTT), 1 mm phenylmethylsulfonyl fluoride (PMSF), 5 μg/ml leupeptin, 5 μg/ml aprotinin, and 1 μg/ml pepstatin A], and centrifuged for 20 s at 800 g  . The pellet was lysed with buffer A added with 0.2% Nonidet P-40 and was centrifuged for 20 s at 800 g  . The resulting pellet was resuspended in buffer A added with 250 mm sucrose and was centrifuged for 20 s at 800 g  to collect nuclei. From the nuclear pellet, nuclear extracts were eluted in buffer B [50 mm HEPES (pH, 7.9), 400 mm KCl, 0.1 mm EDTA, 10% glycerol, 1 mm DTT, 1 mm PMSF, 5 μg/ml leupeptin, 5 μg/ml aprotinin, and 1 μg/ml pepstatin A].
The electrophoretic mobility shift assay was carried out essentially as described previously. 20 The AP-1 binding probe was created by annealing synthetic oligonucleotides, forward (5′-CGCTTGATGAGTCAGCCGGAA-3′) and reverse (5′-TTCCGGCTGACTCATCAAGCG-3′). The annealed probe was 5′-end-labeled with T4 polynucleotide kinase and [γ-32P]ATP. The nuclear extract was incubated with the 32P-labeled probe at room temperature for 15 min. For supershift assay, the nuclear extract was preincubated with c-Fos-, JunB- or c-Jun-specific antibody for 60 min on ice before addition of the 32P-labeled probe. The samples were electrophoresed in 4% acrylamide gel. The gel was then dried and autoradiographed with an intensifying screen at −80°C for 2 days.
Statistical Analysis
Data are expressed as mean ± SD. Statistical analyses of data were performed by one-way analysis of variance, with post hoc  comparison by means of the Dunnett test. Values of P  < 0.05 were considered statistically significant.
Results
MOR-mediated Immediate Early Gene Expression
First, we tested whether MOR activation induces immediate early gene expression by RNA blot hybridization analysis. CROR-B22 cells, CHO cells transformed to express the cloned rat MOR, were stimulated with morphine, an opioid alkaloid agonist acting primarily on MOR, and DAMGO, a synthetic peptide agonist selective for MOR. After agonist stimulation, MOR-mediated c-fos  messenger RNA (mRNA) expression appeared at 10 min, peaked at 30 min, thereafter declined gradually, and returned to the control level by 90 min (fig. 1A). Expression of junB  was also induced by activation of MOR, although the time course of expression was quite different from that of c-fos  expression. The band of junB  mRNA appeared at 10 min and peaked at 30 min but was still remarkable at 90 min after agonist exposure (fig. 1A). The c-fos  and junB  expression was dependent on agonist concentration (fig. 1B), antagonized by naloxone, and inhibited by pretreatment with PTX or PD98059, an inhibitor of the mitogen-activated protein kinase/ERK kinase (MEK)–1, which activates ERKs by phosphorylation (fig. 1C). Thus, our results demonstrate that MOR activation induces transcription of c-fos  and junB  genes via  the PTX-sensitive G-protein (Gior Goor both) and ERK cascade.
Fig. 1. μ-Opioid receptor (MOR)–mediated c-fos  and junB  mRNA expression. Intensities of the β-actin mRNA bands indicate that a nearly equal amount of RNA was loaded in each lane. (A  ) Time course of c-fos  and junB  mRNA expression after 1 μm agonist exposure. (B  ) Dose–response relation for c-fos  and junB  mRNA expression induced by 30-min exposure to the agonists. Lane c is nonstimulation control. (C  ) Pharmacologic analysis of MOR-mediated c-fos  and junB  mRNA expression. After pretreatment with vehicle (lanes 1 and 4), PTX (100 ng/ml; 24 h) (lane 2), or PD98059 (50 μm; 2 h) (lane 3), cells were stimulated with 1 μm agonists for 30 min in the absence (lanes 1, 2, and 3) or presence of 1 μm naloxone (lane 4). DAMGO =[D-Ala2, N  -Me-Phe4,Gly-ol5]enkephalin.
Fig. 1. μ-Opioid receptor (MOR)–mediated c-fos 
	and junB 
	mRNA expression. Intensities of the β-actin mRNA bands indicate that a nearly equal amount of RNA was loaded in each lane. (A 
	) Time course of c-fos 
	and junB 
	mRNA expression after 1 μm agonist exposure. (B 
	) Dose–response relation for c-fos 
	and junB 
	mRNA expression induced by 30-min exposure to the agonists. Lane c is nonstimulation control. (C 
	) Pharmacologic analysis of MOR-mediated c-fos 
	and junB 
	mRNA expression. After pretreatment with vehicle (lanes 1 and 4), PTX (100 ng/ml; 24 h) (lane 2), or PD98059 (50 μm; 2 h) (lane 3), cells were stimulated with 1 μm agonists for 30 min in the absence (lanes 1, 2, and 3) or presence of 1 μm naloxone (lane 4). DAMGO =[D-Ala2, N 
	-Me-Phe4,Gly-ol5]enkephalin.
Fig. 1. μ-Opioid receptor (MOR)–mediated c-fos  and junB  mRNA expression. Intensities of the β-actin mRNA bands indicate that a nearly equal amount of RNA was loaded in each lane. (A  ) Time course of c-fos  and junB  mRNA expression after 1 μm agonist exposure. (B  ) Dose–response relation for c-fos  and junB  mRNA expression induced by 30-min exposure to the agonists. Lane c is nonstimulation control. (C  ) Pharmacologic analysis of MOR-mediated c-fos  and junB  mRNA expression. After pretreatment with vehicle (lanes 1 and 4), PTX (100 ng/ml; 24 h) (lane 2), or PD98059 (50 μm; 2 h) (lane 3), cells were stimulated with 1 μm agonists for 30 min in the absence (lanes 1, 2, and 3) or presence of 1 μm naloxone (lane 4). DAMGO =[D-Ala2, N  -Me-Phe4,Gly-ol5]enkephalin.
×
MOR-mediated Elk-1 Activation
To elucidate the mechanism of MOR-mediated c-fos  and junB  transcription via  ERK cascade, we tested the involvement of a transcription factor, Elk-1, in the MOR signaling pathway, because it has been suggested that Elk-1 phosphorylated by ERK contributes to growth hormone–stimulated c-fos  and junB  expression. 21 CROR-B22 cells were transiently cotransfected with the plasmid encoding Gal4/Elk-1 fusion protein and the plasmid containing luciferase-coding DNA sequence linked with Gal4 binding region. If a serine residue (383Ser) in the Elk-1 region of the Gal4/Elk-1 fusion protein is phosphorylated in the cells, the fusion protein binds to the Gal4 binding region upstream of the luciferase-coding sequence, resulting in an increase in production of luciferase mRNA and protein. Figure 2shows that stimulation of MOR by agonists, DAMGO and morphine, enhanced Elk-1-mediated transcriptional activation of the luciferase reporter gene by about 10-fold, and this activation was inhibited by pretreatment of the cells with PTX and PD98059. This result indicates that stimulation of MOR induces activation of Elk-1, through the action of the PTX-sensitive G-protein and ERK cascade.
Fig. 2. μ-Opioid receptor (MOR) activation induces Elk-1-mediated transcription. Cells were pretreated with pertussis toxin (PTX; 100 ng/ml; 24 h) or PD98059 (50 μm; 2 h), and then stimulated with 1 μm [D-Ala2, N  -Me-Phe4,Gly-ol5]enkephalin (DAMGO) or 1 μm morphine. The ratio of normalized luciferase activity to that of nonstimulated control cells is expressed as mean ± SD from three separate experiments done in duplicate (*P  < 0.05 vs.  nonstimulated control; #P  < 0.05 vs.  cells stimulated by the same agonist without pretreatment).
Fig. 2. μ-Opioid receptor (MOR) activation induces Elk-1-mediated transcription. Cells were pretreated with pertussis toxin (PTX; 100 ng/ml; 24 h) or PD98059 (50 μm; 2 h), and then stimulated with 1 μm [D-Ala2, N 
	-Me-Phe4,Gly-ol5]enkephalin (DAMGO) or 1 μm morphine. The ratio of normalized luciferase activity to that of nonstimulated control cells is expressed as mean ± SD from three separate experiments done in duplicate (*P 
	< 0.05 vs. 
	nonstimulated control; #P 
	< 0.05 vs. 
	cells stimulated by the same agonist without pretreatment).
Fig. 2. μ-Opioid receptor (MOR) activation induces Elk-1-mediated transcription. Cells were pretreated with pertussis toxin (PTX; 100 ng/ml; 24 h) or PD98059 (50 μm; 2 h), and then stimulated with 1 μm [D-Ala2, N  -Me-Phe4,Gly-ol5]enkephalin (DAMGO) or 1 μm morphine. The ratio of normalized luciferase activity to that of nonstimulated control cells is expressed as mean ± SD from three separate experiments done in duplicate (*P  < 0.05 vs.  nonstimulated control; #P  < 0.05 vs.  cells stimulated by the same agonist without pretreatment).
×
MOR-mediated AP-1 Formation
Immediate early gene products belonging to the Fos and Jun families form the dimer AP-1 complex, which activates transcription of a variety of genes by binding to the specific AP-1 binding site located in the 5′-flanking region of the gene. Therefore, we expected that MOR activation could stimulate AP-1–mediated transcriptional activation. CROR-B22 cells were transiently transfected with the plasmid containing luciferase reporter gene linked with seven tandem repeats of AP-1 binding elements, and MOR-mediated luciferase transactivation was measured. As shown in figure 3, MOR activation by agonists stimulated AP-1–mediated transcriptional activity by about twofold, and this activation was inhibited by pretreatment with PTX or PD98059.
Fig. 3. μ-Opioid receptor (MOR) activation induces AP-1–mediated transcription. Cells were pretreated and stimulated in a manner similar to that described in the figure 2legend. The ratio of normalized luciferase activity to that of nonstimulated control cells is expressed as mean ± SD from three separate experiments done in duplicate (*P  < 0.05 vs.  nonstimulated control; #P  < 0.05 vs.  cells stimulated by the same agonist without pretreatment). DAMGO =[D-Ala2, N  -Me-Phe4,Gly-ol5]enkephalin; PTX = pertussis toxin.
Fig. 3. μ-Opioid receptor (MOR) activation induces AP-1–mediated transcription. Cells were pretreated and stimulated in a manner similar to that described in the figure 2legend. The ratio of normalized luciferase activity to that of nonstimulated control cells is expressed as mean ± SD from three separate experiments done in duplicate (*P 
	< 0.05 vs. 
	nonstimulated control; #P 
	< 0.05 vs. 
	cells stimulated by the same agonist without pretreatment). DAMGO =[D-Ala2, N 
	-Me-Phe4,Gly-ol5]enkephalin; PTX = pertussis toxin.
Fig. 3. μ-Opioid receptor (MOR) activation induces AP-1–mediated transcription. Cells were pretreated and stimulated in a manner similar to that described in the figure 2legend. The ratio of normalized luciferase activity to that of nonstimulated control cells is expressed as mean ± SD from three separate experiments done in duplicate (*P  < 0.05 vs.  nonstimulated control; #P  < 0.05 vs.  cells stimulated by the same agonist without pretreatment). DAMGO =[D-Ala2, N  -Me-Phe4,Gly-ol5]enkephalin; PTX = pertussis toxin.
×
Finally, to confirm that c-Fos and JunB expressed by MOR activation indeed form the functional AP-1 complex that can bind with the AP-1 binding sequence, electrophoretic mobility shift assay was performed with use of nuclear extract prepared from agonist-stimulated CROR-B22 cells and the 32P-end-labeled probe containing a consensus AP-1 binding sequence. Figure 4demonstrates that MOR activation by agonists induces an increase in the binding of the nulear protein with the AP-1 probe. This suggests that c-Fos and JunB expressed by MOR activation form the AP-1 complex that can bind with the consensus sequence. Similar to the MOR-mediated c-fos  and junB  mRNA induction, MOR-mediated binding of the AP-1 to the probe was sensitive to PTX and PD98059 (fig. 4A), suggesting the involvement of the PTX-sensitive G-protein and ERK cascade. Supershift assay (fig. 4B) shows that preincubation of the nuclear extract with anti-c-Fos, anti-JunB, or anti-c-Jun antibodies reduces the electrophoretic mobility of the complex of the nuclear protein and the AP-1 binding probe, suggesting that c-Fos, JunB, and c-Jun are involved in the MOR-mediated formation of the AP-1 complex.
Fig. 4. Binding of AP-1 probe with nuclear extracts from CROR-B22 cells. The arrow indicates the labeled AP-1 probe complexed with nuclear protein. (A  ) Effects of pretreatment with PTX (pertussis toxin; 100 ng/ml; 24 h) or PD98059 (50 μm; 2 h). (B  ) Effects of antibodies against immediate early gene products. DAMGO =[D-Ala2, N  -Me-Phe4, Gly-ol5]enkephalin.
Fig. 4. Binding of AP-1 probe with nuclear extracts from CROR-B22 cells. The arrow indicates the labeled AP-1 probe complexed with nuclear protein. (A 
	) Effects of pretreatment with PTX (pertussis toxin; 100 ng/ml; 24 h) or PD98059 (50 μm; 2 h). (B 
	) Effects of antibodies against immediate early gene products. DAMGO =[D-Ala2, N 
	-Me-Phe4, Gly-ol5]enkephalin.
Fig. 4. Binding of AP-1 probe with nuclear extracts from CROR-B22 cells. The arrow indicates the labeled AP-1 probe complexed with nuclear protein. (A  ) Effects of pretreatment with PTX (pertussis toxin; 100 ng/ml; 24 h) or PD98059 (50 μm; 2 h). (B  ) Effects of antibodies against immediate early gene products. DAMGO =[D-Ala2, N  -Me-Phe4, Gly-ol5]enkephalin.
×
Discussion
In the current investigation we demonstrated that MOR activation induces expression of the immediate early genes c-fos  and junB  via  the PTX-sensitive G-protein and ERK cascade, and possibly through the action of the transcription factor Elk-1. Furthermore, the induced immediate early gene products, c-Fos and JunB, are shown to participate in formation of functional AP-1 complex, which can induce expression of other genes. These results are schematically depicted in figure 5. Although further study is necessary to elucidate which genes are activated by this MOR-mediated signal transduction mechanism in vivo  and in CHO cells, it is possible that MOR-mediated gene expression takes part in long-term pharmacologic effects of opioids, such as tolerance and addiction.
Fig. 5. Signal transduction from μ-opioid receptor (MOR) activation to gene expression. The activated Gior Goproteins induce extracellular signal–regulated kinase (ERK) activation through the cascade including Ras, Raf-1, and the mitogen-activated protein kinase/ERK kinase (MEK). It is suggested that ERK induces c-fos  and junB  transcription by phosphorylating a transcription factor Elk-1. The products of c-fos  and junB  participate in formation of AP-1 complex, and induce transcription of other genes. PTX (pertussis toxin) and PD98059 block the signal transduction pathway by affect-ing the G-protein and MEK, respectively. SRF = serum response factor; SRE = serum response element.
Fig. 5. Signal transduction from μ-opioid receptor (MOR) activation to gene expression. The activated Gior Goproteins induce extracellular signal–regulated kinase (ERK) activation through the cascade including Ras, Raf-1, and the mitogen-activated protein kinase/ERK kinase (MEK). It is suggested that ERK induces c-fos 
	and junB 
	transcription by phosphorylating a transcription factor Elk-1. The products of c-fos 
	and junB 
	participate in formation of AP-1 complex, and induce transcription of other genes. PTX (pertussis toxin) and PD98059 block the signal transduction pathway by affect-ing the G-protein and MEK, respectively. SRF = serum response factor; SRE = serum response element.
Fig. 5. Signal transduction from μ-opioid receptor (MOR) activation to gene expression. The activated Gior Goproteins induce extracellular signal–regulated kinase (ERK) activation through the cascade including Ras, Raf-1, and the mitogen-activated protein kinase/ERK kinase (MEK). It is suggested that ERK induces c-fos  and junB  transcription by phosphorylating a transcription factor Elk-1. The products of c-fos  and junB  participate in formation of AP-1 complex, and induce transcription of other genes. PTX (pertussis toxin) and PD98059 block the signal transduction pathway by affect-ing the G-protein and MEK, respectively. SRF = serum response factor; SRE = serum response element.
×
We used a CHO cell line, CROR-B22, permanently transfected with the cloned rat MOR cDNA. This cell line expresses MOR at the level of approximately 10 pmol/mg protein, 6 which is much higher than the expression level of MOR in the brain. 22 The native opioid receptors are predominantly expressed in neuronal cells in the central nervous system. 23 In contrast, CHO cells, which do not endogenously express opioid receptors, 24 are derived from Chinese hamster ovary and do not have neuronal lineage. Therefore, it may be difficult to completely exclude the possibility that MOR expressed in CHO cells is coupled with the signal transduction mechanism, different from that activated by the opioid receptor in the neuronal cells. However, a heterologous expression system using cloned cDNAs has provided a powerful tool for studying the signal transduction mechanism activated by a receptor existing poorly in the neuronal cells, because we can use cultured cells expressing the receptor in a high density. 25 As a next step, we should test whether the MOR-mediated responses observed in CHO cells are also elicited in neuronal cells.
Our data demonstrate that stimulation of MOR induces transcriptional activation mediated by Elk-1, a transcription factor belonging to the ternary complex factor family. 26 Phosphorylated Elk-1 forms a complex with the serum response factor, another transcription factor, and binds to the serum response element of the genes, resulting in transcriptional activation. Serum response elements exist in the promoter of the c-fos  gene 27 as well as in that of the junB  gene. 15,28 Therefore, it is possible that MOR-induced expression of c-fos  and junB  mRNAs involve activation of Elk-1–mediated transcription. However, involvement of transcription factors other than Elk-1 cannot be excluded. For example, serine phosphorylation, possibly mediated by ERKs, is thought to contribute to transcriptional activation mediated by a transcription factor, STAT (signal transducer and activator of transcription), 29 which can bind to the sis  -inducible element in the c-fos  promoter. 30 Further study will be necessary to clarify whether the transcription factor STAT is involved in opioid-activated gene expression via  ERK cascade.
There have been several reports that morphine induces immediate early gene expression in vivo  . Chang et al.  31 demonstrated that c-fos  mRNA levels in rat caudate putamen were increased at 45 min and returned to control level at 90 min after injection with morphine sulfate (10 mg/kg). Garcia et al.  32 showed induction of immediate early gene products, c-Fos, JunB, c-Jun, and a Jun-related antigen, in specific regions of the rat forebrain by acute morphine administration (10 mg/kg). However, they neither investigated the molecular mechanism of the induction nor clarified whether the immediate early gene induction was the result of direct or indirect effect of morphine. In fact, it was reported that intraperitoneal injection of morphine (10 mg/kg) induces expression of c-fos  and junB  in rat striatum and nucleus accumbens and that this immediate early gene induction by MOR is mediated by dopamine D1and N  -methyl-d-aspartate receptors. 33 In contrast, we showed in the current investigation that immediate early gene expression can be directly induced by acute opioid exposure in MOR-expressing cells. It remains to be elucidated whether the mechanism we showed here is relevant in the mammalian central nervous system.
AP-1 complex is a transcriptional activator dimer composed of transcriptional factors belonging to the Fos (c-Fos, FosB, Fra-1, and Fra-2) and Jun (c-Jun, JunB, and JunD) families. 34 Our data showed that MOR stimulation induces AP-1–mediated transcriptional activity and increases binding of nuclear protein to the AP-1 probe. Moreover, we demonstrated that c-Fos, JunB, and c-Jun participate in forming the AP-1 complex. Together, it is conceivable that c-Fos and JunB, the expression of which is induced by MOR activation via  the PTX-sensitive G-protein and ERK cascade, can form functional AP-1 complex and induce expression of other proteins. The involvement of AP-1 complex in opioid-induced alteration of gene expression in vivo  has not been shown previously. However, it is possible that opioid-induced AP-1 complex formation contributes to physiologic responses to opioids in vivo  . The genes encoding opioid peptide precursors, including proopiomelanocortin, preproenkephalin, and prodynorphin, are known to contain AP-1 binding sites. 35–37 It has been shown that expression of preproenkephalin and prodynorphin is suppressed during prolonged morphine administration. 38,39 On the other hand, Chang et al.  40 demonstrated that repeated morphine exposure causes significant induction of proopiomelanocortin mRNA in SH-SY5Y human neuroblastoma cells. Opioid-induced AP-1 formation, which was demonstrated in the current study, might be the molecular basis of this phenomenon. Furthermore, chronic morphine administration increases expression of the β-adrenergic receptor kinase (βARK) in the rat locus coeruleus. 41 βARK promotes desensitization of the opioid receptors by phosphorylation 42 and may contribute to morphine tolerance. 43 It will be interesting to examine the involvement of morphine-induced immediate early gene expression and AP-1 formation in the induction of βARK expression by morphine.
Opioid-induced changes in gene expression may be manifested also in the immune system. Hedin et al.  44 reported that activation of the δ-opioid receptor expressed by transfection with the cloned cDNA leads to increased c-fos  mRNA and AP-1 complex in Jurkat T lymphocytes and results in enhancement of interleukin-2 secretion. On the other hand, it was reported that some sets of immune cells endogenously express MOR 45 and that administration of morphine causes an enhanced release of interleukin-2. 46 It is likely that MOR activation induces interleukin-2 release via  c-fos  induction and AP-1 formation, similar to that with the cloned δ-opioid receptor, because it has been shown that the intracellular signal transduction mechanism activated by MOR is essentially the same as that activated by δ-opioid receptor. 6 Thus, it may be possible that administration of opioids could affect the immune system via  AP-1–mediated transcription.
In conclusion, we showed that MOR activation induces immediate early gene expression and elevates AP-1–mediated transcriptional activity via  ERK cascade in CHO cells. Our findings suggest that administration of opioids induces a wide range of gene-expression changes, not only in the central nervous system but also in the immune system.
The authors thank Natsumi Kikkawa and Kanako Murata (Technical Assistants, Department of Anesthesia, Kyoto University Hospital, Kyoto, Japan) for technical assistance and Etsuko Kobayashi (Secretary, Department of Anesthesia, Kyoto University Hospital) for secretarial assistance.
References
Leslie FM: Methods used for the study of opioid receptors. Pharmacol Rev 1987; 39: 197–249Leslie, FM
Matthes HWD, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Le Meur M, Dollé P, Tzavara E, Hanoune J, Roques BP, Kieffer BL: Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the μ-opioid-receptor gene. Nature 1996; 383: 819–23Matthes, HWD Maldonado, R Simonin, F Valverde, O Slowe, S Kitchen, I Befort, K Dierich, A Le Meur, M Dollé, P Tzavara, E Hanoune, J Roques, BP Kieffer, BL
Sora I, Takahashi N, Funada M, Ujike H, Revay RS, Donovan DM, Miner LL, Uhl GR: Opiate receptor knockout mice define μ receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci U S A 1997; 94: 1544–9Sora, I Takahashi, N Funada, M Ujike, H Revay, RS Donovan, DM Miner, LL Uhl, GR
Jordan B, Devi LA: Molecular mechanisms of opioid receptor signal transduction. Br J Anaesth 1998; 81: 12–9Jordan, B Devi, LA
Reisine T: Opiate receptors. Neuropharmacology 1995; 34: 463–72Reisine, T
Fukuda K, Kato S, Morikawa H, Shoda T, Mori K: Functional coupling of the δ-, μ-, and κ-opioid receptors to mitogen-activated protein kinase and arachidonate release in Chinese hamster ovary cells. J Neurochem 1996; 67: 1309–16Fukuda, K Kato, S Morikawa, H Shoda, T Mori, K
Gutstein HB, Rubie EA, Mansour A, Akil H, Woodgett JR: Opioid effects on mitogen-activated protein kinase signaling cascades. A nesthesiology 1997; 87: 1118–26Gutstein, HB Rubie, EA Mansour, A Akil, H Woodgett, JR
Li LY, Chang KJ: The stimulatory effect of opioids on mitogen-activated protein kinase in Chinese hamster ovary cells transfected to express μ-opioid receptors. Mol Pharmacol 1996; 50: 599–602Li, LY Chang, KJ
van Biesen T, Luttrell LM, Hawes BE, Lefkowitz RJ: Mitogenic signaling via G protein–coupled receptors. Endocrine Rev 1996; 17: 698–714van Biesen, T Luttrell, LM Hawes, BE Lefkowitz, RJ
Kornhauser JM, Greenberg ME: A kinase to remember: Dual roles for MAP kinase in long-term memory. Neuron 1997; 18: 839–42Kornhauser, JM Greenberg, ME
Davis RJ: The mitogen-activated protein kinase signal transduction pathway. J Biol Chem 1993; 268: 14553–6Davis, RJ
Kato S, Fukuda K, Morikawa H, Shoda T, Mima H, Mori K: Adaptations to chronic agonist exposure of μ-opioid receptor-expressing Chinese hamster ovary cells. Eur J Pharmacol 1998; 345: 221–8Kato, S Fukuda, K Morikawa, H Shoda, T Mima, H Mori, K
Mishina M, Takai T, Imoto K, Noda M, Takahashi T, Numa S, Methfessel C, Sakmann B: Molecular distinction between fetal and adult forms of muscle acetylcholine receptor. Nature 1986; 321: 406–11Mishina, M Takai, T Imoto, K Noda, M Takahashi, T Numa, S Methfessel, C Sakmann, B
van Straaten F, Müller R, Curran T, Van Beveren C, Verma IM: Complete nucleotide sequence of a human c-onc  gene: Deduced amino acid sequence of the human c-fos  protein. Proc Natl Acad Sci U S A 1983; 80: 3183–7van Straaten, F Müller, R Curran, T Van Beveren, C Verma, IM
Perez-Albuerne ED, Schatteman G, Sanders LK, Nathans D: Transcriptional regulatory elements downstream of the JunB gene. Proc Natl Acad Sci U S A 1993; 90: 11960–4Perez-Albuerne, ED Schatteman, G Sanders, LK Nathans, D
Nakajima-Iijima S, Hamada H, Reddy P, Kakunaga T: Molecular structure of the human cytoplasmic β-actin gene: Interspecies homology of sequences in the introns. Proc Natl Acad Sci U S A 1985; 82: 6133–7Nakajima-Iijima, S Hamada, H Reddy, P Kakunaga, T
Feinberg AP, Vogelstein B: A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 1983; 132: 6–13Feinberg, AP Vogelstein, B
Portier M, Combes T, Gully D, Maffrand JP, Casellas P: Neurotensin type 1 receptor–mediated activation of krox24  , c-fos  and Elk-1: Preventing effect of the neurotensin antagonists SR 48692 and SR 142948. FEBS Lett 1998; 432: 88–93Portier, M Combes, T Gully, D Maffrand, JP Casellas, P
Lin A, Minden A, Martinetto H, Claret FX, Lange-Carter C, Mercurio F, Johnson GL, Karin M: Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2. Science 1995; 268: 286–90Lin, A Minden, A Martinetto, H Claret, FX Lange-Carter, C Mercurio, F Johnson, GL Karin, M
Guo Z, Du X, Iacovitti L: Regulation of tyrosine hydroxylase gene expression during transdifferentiation of striatal neurons: Changes in transcription factors binding the AP-1 site. J Neurosci 1998; 18: 8163–74Guo, Z Du, X Iacovitti, L
Hodge C, Liao J, Stofega M, Guan K, Carter-Su C, Schwartz J: Growth hormone stimulates phosphorylation and activation of Elk-1 and expression of c-fos  , egr-1  , and junB  through activation of extracellular signal–regulated kinases 1 and 2. J Biol Chem 1998; 273: 31327–36Hodge, C Liao, J Stofega, M Guan, K Carter-Su, C Schwartz, J
Goldstein A, Naidu A: Multiple opioid receptors: Ligand selectivity profiles and binding site signatures. Mol Pharmacol 1989; 36: 265–72Goldstein, A Naidu, A
Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ: Anatomy of CNS opioid receptors. Trends Neurosci 1988; 11: 308–14Mansour, A Khachaturian, H Lewis, ME Akil, H Watson, SJ
Chakrabarti S, Prather PL, Yu L, Law PY, Loh HH: Expression of the μ-opioid receptor in CHO cells: Ability of μ-opioid ligands to promote α-azidoanilido[32P]GTP labeling of multiple G protein α subunits. J Neurochem 1995; 64: 2534–43Chakrabarti, S Prather, PL Yu, L Law, PY Loh, HH
Fukuda K, Kato S, Shoda T, Morikawa H, Mima H, Mori K: Partial agonistic activity of naloxone on the opioid receptors expressed from complementary deoxyribonucleic acids in Chinese hamster ovary cells. Anesth Analg 1998; 87: 450–5Fukuda, K Kato, S Shoda, T Morikawa, H Mima, H Mori, K
Treisman R: The serum response element. Trends Biochem Sci 1992; 17: 423–6Treisman, R
Treisman R: Identification of a protein-binding site that mediates transcriptional response of the c-fos  gene to serum factors. Cell 1986; 46: 567–74Treisman, R
Kitabayashi I, Kawakami Z, Matsuoka T, Chiu R, Gachelin G, Yokoyama K: Two cis  -regulatory elements that mediate different signaling pathways for serum-dependent activation of the junB  gene. J Biol Chem 1993; 268: 14882–9Kitabayashi, I Kawakami, Z Matsuoka, T Chiu, R Gachelin, G Yokoyama, K
Zhang X, Blenis J, Li HC, Schindler C, Chen-Kiang S: Requirement of serine phosphorylation for formation of STAT-promoter complexes. Science 1995; 267: 1990–4Zhang, X Blenis, J Li, HC Schindler, C Chen-Kiang, S
Campbell GS, Meyer DJ, Raz R, Levy DE, Schwartz J, Carter-Su C: Activation of acute phase response factor (APRF)/Stat3 transcription factor by growth hormone. J Biol Chem 1995; 270: 3974–9Campbell, GS Meyer, DJ Raz, R Levy, DE Schwartz, J Carter-Su, C
Chang SL, Squinto SP, Harlan RE: Morphine activation of c-FOS expression in rat brain. Biochem Biophys Res Commun 1988; 157: 698–704Chang, SL Squinto, SP Harlan, RE
Garcia MM, Brown HE, Harlan RE: Alterations in immediate-early gene proteins in the rat forebrain induced by acute morphine injection. Brain Res 1995; 692: 23–40Garcia, MM Brown, HE Harlan, RE
Liu J, Nickolenko J, Sharp FR: Morphine induces c-fos  and junB  in striatum and nucleus accumbens via D1and N  -methyl-D-aspartate receptors. Proc Natl Acad Sci U S A 1994; 91: 8537–41Liu, J Nickolenko, J Sharp, FR
Karin M: The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 1995; 270: 16483–6Karin, M
Sonnenberg JL, Rauscher FJ III, Morgan JI, Curran T: Regulation of proenkephalin by Fos and Jun. Science 1989; 246: 1622–5Sonnenberg, JL Rauscher, FJ Morgan, JI Curran, T
Naranjo JR, Mellström B, Achaval M, Sassone-Corsi P: Molecular pathways of pain: Fos/Jun-mediated activation of a noncanonical AP-1 site in the prodynorphin gene. Neuron 1991; 6: 607–17Naranjo, JR Mellström, B Achaval, M Sassone-Corsi, P
Therrien M, Drouin J: Pituitary pro-opiomelanocortin gene expression requires synergistic interactions of several regulatory elements. Mol Cell Biol 1991; 11: 3492–503Therrien, M Drouin, J
Uhl GR, Ryan JP, Schwartz JP: Morphine alters preproenkephalin gene expression. Brain Res 1988; 459: 391–7Uhl, GR Ryan, JP Schwartz, JP
Romualdi P, Lesa G, Ferri S: Chronic opiate agonists down-regulate prodynorphin gene expression in rat brain. Brain Res 1991; 563: 132–6Romualdi, P Lesa, G Ferri, S
Chang SL, Zadina JE, Spriggs L, Squinto SP: Prolonged activation of c-fos  and optimal activation of pro-opiomelanocortin mRNA after repeated morphine exposure in SH-SY5Y cells. Mol Cell Neurosci 1993; 4: 25–9Chang, SL Zadina, JE Spriggs, L Squinto, SP
Terwilliger RZ, Ortiz J, Guitart X, Nestler EJ: Chronic morphine administration increases β-adrenergic receptor kinase (βARK) levels in the rat locus coeruleus. J Neurochem 1994; 63: 1983–6Terwilliger, RZ Ortiz, J Guitart, X Nestler, EJ
Yu Y, Zhang L, Yin X, Sun H, Uhl GR, Wang JB:μ Opioid receptor phosphorylation, desensitization, and ligand efficacy. J Biol Chem 1997; 272: 28869–74Yu, Y Zhang, L Yin, X Sun, H Uhl, GR Wang, JB
Bohn LM, Gainetdinov RR, Lin FT, Lefkowitz RJ, Caron MG:μ-Opioid receptor desensitization by β-arrestin-2 determines morphine tolerance but not dependence. Nature 2000; 408: 720–3Bohn, LM Gainetdinov, RR Lin, FT Lefkowitz, RJ Caron, MG
Hedin KE, Bell MP, Kalli KR, Huntoon CJ, Sharp BM, McKean DJ:δ-Opioid receptors expressed by Jurkat T cells enhance IL-2 secretion by increasing AP-1 complexes and activity of the NF-AT/AP-1-binding promoter element. J Immunol 1997; 159: 5431–40Hedin, KE Bell, MP Kalli, KR Huntoon, CJ Sharp, BM McKean, DJ
Chuang TK, Killam KF Jr, Chuang LF, Kung HF, Sheng WS, Chao CC, Yu L, Chuang RY: Mu opioid receptor gene expression in immune cells. Biochem Biophys Res Commun 1995; 216: 922–30Chuang, TK Killam, KF Chuang, LF Kung, HF Sheng, WS Chao, CC Yu, L Chuang, RY
Chuang LF, Killam KF Jr, Chuang RY: Opioid dependency and T-helper cell functions in rhesus monkey. In Vivo 1993; 7: 159–66Chuang, LF Killam, KF Chuang, RY
Fig. 1. μ-Opioid receptor (MOR)–mediated c-fos  and junB  mRNA expression. Intensities of the β-actin mRNA bands indicate that a nearly equal amount of RNA was loaded in each lane. (A  ) Time course of c-fos  and junB  mRNA expression after 1 μm agonist exposure. (B  ) Dose–response relation for c-fos  and junB  mRNA expression induced by 30-min exposure to the agonists. Lane c is nonstimulation control. (C  ) Pharmacologic analysis of MOR-mediated c-fos  and junB  mRNA expression. After pretreatment with vehicle (lanes 1 and 4), PTX (100 ng/ml; 24 h) (lane 2), or PD98059 (50 μm; 2 h) (lane 3), cells were stimulated with 1 μm agonists for 30 min in the absence (lanes 1, 2, and 3) or presence of 1 μm naloxone (lane 4). DAMGO =[D-Ala2, N  -Me-Phe4,Gly-ol5]enkephalin.
Fig. 1. μ-Opioid receptor (MOR)–mediated c-fos 
	and junB 
	mRNA expression. Intensities of the β-actin mRNA bands indicate that a nearly equal amount of RNA was loaded in each lane. (A 
	) Time course of c-fos 
	and junB 
	mRNA expression after 1 μm agonist exposure. (B 
	) Dose–response relation for c-fos 
	and junB 
	mRNA expression induced by 30-min exposure to the agonists. Lane c is nonstimulation control. (C 
	) Pharmacologic analysis of MOR-mediated c-fos 
	and junB 
	mRNA expression. After pretreatment with vehicle (lanes 1 and 4), PTX (100 ng/ml; 24 h) (lane 2), or PD98059 (50 μm; 2 h) (lane 3), cells were stimulated with 1 μm agonists for 30 min in the absence (lanes 1, 2, and 3) or presence of 1 μm naloxone (lane 4). DAMGO =[D-Ala2, N 
	-Me-Phe4,Gly-ol5]enkephalin.
Fig. 1. μ-Opioid receptor (MOR)–mediated c-fos  and junB  mRNA expression. Intensities of the β-actin mRNA bands indicate that a nearly equal amount of RNA was loaded in each lane. (A  ) Time course of c-fos  and junB  mRNA expression after 1 μm agonist exposure. (B  ) Dose–response relation for c-fos  and junB  mRNA expression induced by 30-min exposure to the agonists. Lane c is nonstimulation control. (C  ) Pharmacologic analysis of MOR-mediated c-fos  and junB  mRNA expression. After pretreatment with vehicle (lanes 1 and 4), PTX (100 ng/ml; 24 h) (lane 2), or PD98059 (50 μm; 2 h) (lane 3), cells were stimulated with 1 μm agonists for 30 min in the absence (lanes 1, 2, and 3) or presence of 1 μm naloxone (lane 4). DAMGO =[D-Ala2, N  -Me-Phe4,Gly-ol5]enkephalin.
×
Fig. 2. μ-Opioid receptor (MOR) activation induces Elk-1-mediated transcription. Cells were pretreated with pertussis toxin (PTX; 100 ng/ml; 24 h) or PD98059 (50 μm; 2 h), and then stimulated with 1 μm [D-Ala2, N  -Me-Phe4,Gly-ol5]enkephalin (DAMGO) or 1 μm morphine. The ratio of normalized luciferase activity to that of nonstimulated control cells is expressed as mean ± SD from three separate experiments done in duplicate (*P  < 0.05 vs.  nonstimulated control; #P  < 0.05 vs.  cells stimulated by the same agonist without pretreatment).
Fig. 2. μ-Opioid receptor (MOR) activation induces Elk-1-mediated transcription. Cells were pretreated with pertussis toxin (PTX; 100 ng/ml; 24 h) or PD98059 (50 μm; 2 h), and then stimulated with 1 μm [D-Ala2, N 
	-Me-Phe4,Gly-ol5]enkephalin (DAMGO) or 1 μm morphine. The ratio of normalized luciferase activity to that of nonstimulated control cells is expressed as mean ± SD from three separate experiments done in duplicate (*P 
	< 0.05 vs. 
	nonstimulated control; #P 
	< 0.05 vs. 
	cells stimulated by the same agonist without pretreatment).
Fig. 2. μ-Opioid receptor (MOR) activation induces Elk-1-mediated transcription. Cells were pretreated with pertussis toxin (PTX; 100 ng/ml; 24 h) or PD98059 (50 μm; 2 h), and then stimulated with 1 μm [D-Ala2, N  -Me-Phe4,Gly-ol5]enkephalin (DAMGO) or 1 μm morphine. The ratio of normalized luciferase activity to that of nonstimulated control cells is expressed as mean ± SD from three separate experiments done in duplicate (*P  < 0.05 vs.  nonstimulated control; #P  < 0.05 vs.  cells stimulated by the same agonist without pretreatment).
×
Fig. 3. μ-Opioid receptor (MOR) activation induces AP-1–mediated transcription. Cells were pretreated and stimulated in a manner similar to that described in the figure 2legend. The ratio of normalized luciferase activity to that of nonstimulated control cells is expressed as mean ± SD from three separate experiments done in duplicate (*P  < 0.05 vs.  nonstimulated control; #P  < 0.05 vs.  cells stimulated by the same agonist without pretreatment). DAMGO =[D-Ala2, N  -Me-Phe4,Gly-ol5]enkephalin; PTX = pertussis toxin.
Fig. 3. μ-Opioid receptor (MOR) activation induces AP-1–mediated transcription. Cells were pretreated and stimulated in a manner similar to that described in the figure 2legend. The ratio of normalized luciferase activity to that of nonstimulated control cells is expressed as mean ± SD from three separate experiments done in duplicate (*P 
	< 0.05 vs. 
	nonstimulated control; #P 
	< 0.05 vs. 
	cells stimulated by the same agonist without pretreatment). DAMGO =[D-Ala2, N 
	-Me-Phe4,Gly-ol5]enkephalin; PTX = pertussis toxin.
Fig. 3. μ-Opioid receptor (MOR) activation induces AP-1–mediated transcription. Cells were pretreated and stimulated in a manner similar to that described in the figure 2legend. The ratio of normalized luciferase activity to that of nonstimulated control cells is expressed as mean ± SD from three separate experiments done in duplicate (*P  < 0.05 vs.  nonstimulated control; #P  < 0.05 vs.  cells stimulated by the same agonist without pretreatment). DAMGO =[D-Ala2, N  -Me-Phe4,Gly-ol5]enkephalin; PTX = pertussis toxin.
×
Fig. 4. Binding of AP-1 probe with nuclear extracts from CROR-B22 cells. The arrow indicates the labeled AP-1 probe complexed with nuclear protein. (A  ) Effects of pretreatment with PTX (pertussis toxin; 100 ng/ml; 24 h) or PD98059 (50 μm; 2 h). (B  ) Effects of antibodies against immediate early gene products. DAMGO =[D-Ala2, N  -Me-Phe4, Gly-ol5]enkephalin.
Fig. 4. Binding of AP-1 probe with nuclear extracts from CROR-B22 cells. The arrow indicates the labeled AP-1 probe complexed with nuclear protein. (A 
	) Effects of pretreatment with PTX (pertussis toxin; 100 ng/ml; 24 h) or PD98059 (50 μm; 2 h). (B 
	) Effects of antibodies against immediate early gene products. DAMGO =[D-Ala2, N 
	-Me-Phe4, Gly-ol5]enkephalin.
Fig. 4. Binding of AP-1 probe with nuclear extracts from CROR-B22 cells. The arrow indicates the labeled AP-1 probe complexed with nuclear protein. (A  ) Effects of pretreatment with PTX (pertussis toxin; 100 ng/ml; 24 h) or PD98059 (50 μm; 2 h). (B  ) Effects of antibodies against immediate early gene products. DAMGO =[D-Ala2, N  -Me-Phe4, Gly-ol5]enkephalin.
×
Fig. 5. Signal transduction from μ-opioid receptor (MOR) activation to gene expression. The activated Gior Goproteins induce extracellular signal–regulated kinase (ERK) activation through the cascade including Ras, Raf-1, and the mitogen-activated protein kinase/ERK kinase (MEK). It is suggested that ERK induces c-fos  and junB  transcription by phosphorylating a transcription factor Elk-1. The products of c-fos  and junB  participate in formation of AP-1 complex, and induce transcription of other genes. PTX (pertussis toxin) and PD98059 block the signal transduction pathway by affect-ing the G-protein and MEK, respectively. SRF = serum response factor; SRE = serum response element.
Fig. 5. Signal transduction from μ-opioid receptor (MOR) activation to gene expression. The activated Gior Goproteins induce extracellular signal–regulated kinase (ERK) activation through the cascade including Ras, Raf-1, and the mitogen-activated protein kinase/ERK kinase (MEK). It is suggested that ERK induces c-fos 
	and junB 
	transcription by phosphorylating a transcription factor Elk-1. The products of c-fos 
	and junB 
	participate in formation of AP-1 complex, and induce transcription of other genes. PTX (pertussis toxin) and PD98059 block the signal transduction pathway by affect-ing the G-protein and MEK, respectively. SRF = serum response factor; SRE = serum response element.
Fig. 5. Signal transduction from μ-opioid receptor (MOR) activation to gene expression. The activated Gior Goproteins induce extracellular signal–regulated kinase (ERK) activation through the cascade including Ras, Raf-1, and the mitogen-activated protein kinase/ERK kinase (MEK). It is suggested that ERK induces c-fos  and junB  transcription by phosphorylating a transcription factor Elk-1. The products of c-fos  and junB  participate in formation of AP-1 complex, and induce transcription of other genes. PTX (pertussis toxin) and PD98059 block the signal transduction pathway by affect-ing the G-protein and MEK, respectively. SRF = serum response factor; SRE = serum response element.
×